Myocardial Protection Of L-carnitine In Patients With Coronary Heart Disease Undergoing Percutaneous Coronary Intervention

OBJECTIVE To evaluate the myocardial protection effects of L-carnitine in patients with coronary heart disease undergoing primary percutaneous coronary intervention(PCI) . METHODS vein treatment group: 96 consecutive patients with NSTE-ACS undergoing primary PCI were randomized to two groups in 48h were randomized to two groups ,the L-CN treated group(n=48) and control group(n=48). L-CN 5g was infused into vein 30min previous PCI and L-CN10g was infused into vein after PCI in the L-CN treated group in three days. Normal saline replace L-CN was infused into vein in control group, oral administration treatment group: 110 consecutive patients with coronary heart disease undergoing primary PCI were randomized to two groups ,the L-CN treated group(n=55) and control group(n=55) .The peak value of CK-MB and TnI before and after PCI were observed .The combined cardiovascular events(a combination of cardiac death,nonfatal myocardial infarction and the re-hospital admission due to recurrent ischemia angina) within 30 days after PCI were analyzed. RESULTS In L-CN treated group,the peak value of CK-MB was significantly lower than the control group at 12h and 24h after PCI(P<0.01).The peak value of TnI in the treatment group were also significantly lower than the control group at 8h(P<0.01),12h and 24h(P<0.05) after PCI. The combined cardiovascular events during or 30d after PCI was markedly reduced in the L-CN treated group. CONCLUSION L-CN adjunct therapy appears to be associated with a reduced level of cardiac markers in patients with CHD. These results support a larger clinical trial to investigate the effect of L-carntine on cardiac events following PCI.